Aclaris’ Bosakitug Trial Misses Key Atopic Dermatitis Targets
The Phase 2 study missed its primary and secondary endpoints, while Aclaris said the drug was generally well tolerated.
Makkler Newsroom · Nov 16, 11:50 AM · 1 min read
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO